Hims & Hers (HIMS) Stock; Climbs 8% as FDA Peptide Review Sparks Expansion Hopes

TLDRs;

• Hims & Hers shares rose as FDA reconsideration of peptide rules lifted investor sentiment across biotech markets.
• Regulatory review of peptides like BPC-157 and TB-500 raises potential new growth channels for telehealth expansion.
• Company is diversifying beyond GLP-1 drugs through acquisitions and partnerships with major pharmaceutical players.
• Despite optimism, FDA review remains early-stage and no commercial peptide rollout timeline has been confirmed.

Hims & Hers Health saw its shares rise sharply as investors reacted to a key regulatory development from Washington. The stock climbed about 8% during trading, reflecting renewed optimism that the company could benefit from a potential easing of restrictions on several peptide-based therapies.

The move follows news that the U.S. Food and Drug Administration is reconsidering how certain peptides are regulated, a shift that could eventually open new commercial pathways for telehealth and compounded drug providers.

The FDA’s renewed attention on peptides has been viewed by the market as more than just a regulatory update, it signals a possible structural change in how emerging biologic-like compounds are handled in compounding pharmacies.

FDA Reopens Regulatory Debate

The catalyst behind the rally is the FDA’s decision to revisit rules surrounding a group of peptides, including compounds such as BPC-157, TB-500, KPV, and MOTS-c. The agency is preparing an advisory panel scheduled for late July to determine whether compounding pharmacies should be allowed broader access to these substances.

Hims & Hers Health, Inc., HIMS

In parallel, the FDA has also begun removing several peptides from its Category 2 safety-risk classification list after certain nominations were withdrawn. While this does not immediately change enforcement policy, it has been interpreted by investors as an early sign of regulatory softening.

These peptides had previously been restricted after regulators raised concerns about purity, toxicity risks, and immune system reactions. A tightening of rules in 2023 significantly reduced compounding activity, creating a more cautious operating environment for companies exposed to the space.

Hims Pushes Beyond GLP-1 Dependency

For Hims & Hers, the regulatory shift arrives at a critical moment. The company has been working to diversify its business beyond the GLP-1 category, which includes weight-loss and diabetes-related treatments that recently faced increased FDA scrutiny.

Earlier this year, Hims briefly introduced a low-cost compounded semaglutide option before pulling it after regulatory warnings about copycat formulations. The company quickly pivoted, later partnering with Novo Nordisk to distribute branded GLP-1 medications such as Wegovy and Ozempic through its platform.

Management has repeatedly emphasized that its revenue base is increasingly diversified, with non-GLP-1 services accounting for a large share of U.S. operations. Investors are now watching closely to see whether peptides could become the next growth engine.

Supply Chain Strategy Comes Into Focus

Hims & Hers is not approaching the potential opportunity passively. In 2025, the company acquired a peptide manufacturing facility in California, a move aimed at strengthening its domestic supply chain and reducing reliance on external compounding networks.

That investment is now gaining renewed attention as FDA discussions move forward. If regulatory clarity improves, the facility could position Hims to scale peptide-related offerings more quickly than competitors who lack in-house production capabilities.

Chief Medical Officer Dr. Pat Carroll recently noted that evolving FDA guidance could help shift peptide treatments “out of the gray market and into more trusted channels,” highlighting the company’s interest in expanding responsibly within regulatory boundaries.

For now, investors are trading on expectations rather than confirmed product launches. Hims & Hers has not provided revenue forecasts tied to peptides, nor has it set a clear commercialization timeline. Until then, the stock remains driven by regulatory headlines, positioning Hims at the center of a rapidly evolving debate between innovation and oversight in the emerging peptide economy.

The post Hims & Hers (HIMS) Stock; Climbs 8% as FDA Peptide Review Sparks Expansion Hopes appeared first on CoinCentral.